STOCK TITAN

Iovance Biotherapeutics Inc - IOVA STOCK NEWS

Welcome to our dedicated news page for Iovance Biotherapeutics (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Iovance Biotherapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Iovance Biotherapeutics's position in the market.

Rhea-AI Summary
Iovance Biotherapeutics granted 79,310 stock options to new employees under the 2021 Inducement Plan. Each option has an exercise price of $11.72 and vests over a three-year period. The awards were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for new employees. The options cover 97,700 shares with an exercise price of $15.02. Each option vests over a three-year period, encouraging retention of employees.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.26%
Tags
none
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (IOVA) receives FDA clearance to resume patient enrollment in the IOV-LUN-202 trial for LN-145 TIL cell therapy in non-small cell lung cancer. Preliminary data indicates potential benefits of more durable responses compared to second-line chemotherapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
none
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) announces senior leadership's participation in upcoming healthcare conferences. The company will present at TD Cowen's, Barclays', and H.C. Wainwright's events to discuss novel polyclonal TIL therapies for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.01%
Tags
conferences
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the successful U.S. launch of Amtagvi™, the first and only one-time, individualized T cell therapy for solid tumor cancer. The company also reports progress in regulatory submissions for Amtagvi in the European Union, United Kingdom, and Canada. Fourth quarter and full year 2023 financial results and corporate updates were shared, highlighting healthy demand and momentum for Amtagvi.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.72%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. (IOVA) will announce its Q4 and full-year 2023 financial results on February 28, 2024. The company focuses on developing TIL therapies for cancer patients. A conference call and webcast will discuss the results and provide a corporate update.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.08%
Tags
conferences earnings
Rhea-AI Summary
WuXi Advanced Therapies Receives FDA Approval for AMTAGVI, a One-Time T Cell Therapy for Solid Tumor Cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces the pricing of an underwritten offering of 23,014,000 shares of its common stock at $9.15 per share, aiming to raise approximately $211 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
31.48%
Tags
-
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announced the approval of inducement stock options for new employees. The options cover 40,450 shares with an exercise price of $9.87 per share, vesting over a three-year period.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Iovance Biotherapeutics, Inc. announces FDA approval for novel polyclonal TIL therapies for cancer patients. The company will host a conference call and live webcast to discuss the approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.29%
Tags
conferences
Iovance Biotherapeutics Inc

Nasdaq:IOVA

IOVA Rankings

IOVA Stock Data

3.45B
210.92M
0.56%
89.18%
16.6%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
San Carlos

About IOVA

iovance biotherapeutics is focused on the development and commercialization of novel cancer immunotherapies based on tumor infiltrating lymphocytes (til). this approach, also known as adoptive t-cell therapy, was initially developed by dr. steven a. rosenberg at the national cancer institute (nci). in phase 2 clinical trials conducted at the nci, 56% and 24% of patients treated with this technology were reported by nci to have achieved objective and complete response criteria, respectively. our lead product candidate is an autologous, ready-to-infuse cell therapy, that has demonstrated distinctive efficacy in the treatment of metastatic melanoma. in addition to metastatic melanoma, carcinoma of the head and neck and cervical cancer our til therapy technology is potentially applicable to many other tumor types, including ovarian, breast, bladder, colorectal and other cancers. as we continue advancing our current clinical programs through the introduction of manufacturing and logistical